Canada: Prosecute With Candour In Canada

Last Updated: January 11 2011
Article by Nathaniel Lipkus and Shonagh McVean

Originally published February 2010 in Managing IP.

Patent prosecution in Canada is often managed from abroad and typically takes a back seat to prosecution of corresponding patents in larger markets, such as the US and Europe. In fact, only 12% of Canadian patent applications are filed by Canadians, with only one of the top 10 patentees (Schlumberger Canada) and only two of the top 10 patent applicants (Schlumberger Canada and Research in Motion) based in Canada (see chart on page 25).

A December 2009 decision from Canada's Federal Court threatens to upturn the top-down manner of prosecuting Canadian applications. The Court in Lundbeck Canada Inc v Ratiopharm Inc (known as the Memantine decision) determined that patent applicants and their Canadian agents must be full and frank in their responses to examiner requisitions in order to fulfil their so-called duty of candour. Practically speaking, however, it is too early to know precisely what conduct will fulfil this duty, which is now indeterminate in its scope (see box on page 26).

A new set of risks

Consider a Canadian application that is prosecuted following preliminary findings of invalidity of the proposed claims of a corresponding US application, which were overcome by narrowing the US claims. The Canadian examiner will have the benefit of all the prior art that was before the USPTO and may look to the US prosecution history and find the proposed claims to be invalid on the basis of the same prior art that concerned the US examiner.

Until Memantine, dealing with this situation in Canada was straightforward: advocate fiercely that the subject matter in the application is inventive over the prior art of interest. Although the Patent Act is clear that patent applications are required to behave in good faith in replying to office actions, never had a Canadian court rendered a patent unenforceable on the basis of the forcefulness with which an applicant responded to prior art allegations. Memantine complicates matters. The Memantine judge imposed a new standard of practice on Canadian patent agents in replying to office actions containing prior art allegations.

In his opinion, the judge said: "A proper understanding of the prior art is clearly critical to patent examination. The duty of good faith ... requires that this prior art be fully and fairly described by applicants and their agents when answering requisitions from the Patent Office."

This passage suggests that Canadian patent agents and their clients may no longer passionately advocate that an application is inventive over the prior art, as is traditionally done. Rather, a dispassionate view of all known prior art appears to be required. This "full and fair" approach far exceeds the US standard, which merely requires that applicants not intentionally deceive the Patent Office in respect of information material to patentability.

Under these circumstances, Canadian patent agents are now expressing serious concerns about how they are to address prior art allegations in responses to office actions, including whether they should make any arguments at all.

A new defence to patent infringement?

With patent prosecution perceived as a cost centre rather than revenue generator in innovative businesses, there is a temptation to continue with the status quo (subordinating Canadian prosecution to prosecution in more lucrative foreign markets) as a cost-saving measure. However, this could have long ranging consequences.

Post-Memantine, patent infringement defendants now smell blood in the water and are adapting their litigation strategies to advance duty of candour allegations. It is a safe bet that if a patent is important enough to be the subject of infringement litigation in Canada, then Canadian defence counsel will avail themselves of any defence available based on a violation of the duty of candour by the plaintiff. In one example, not one week after publication of the Memantine decision, a client of this author's firm faced a barrage of attacks on its patent based on an alleged duty of candour violation.

The duty of candour stems from a provision in Canada's Patent Act, which deems a patent application to be abandoned if the applicant does not "reply in good faith to any requisition made by an examiner in connection with an examination" within a specified time period. The Patent Office will not notify the applicant if the patent has been abandoned; rather, it is not until the patent becomes contentious in the marketplace that potential infringers will retrospectively allege that the patent was irretrievably abandoned at the time of the alleged bad faith.

This development obviously introduces enormous uncertainty for patentees, applicants and Canadian patent agents seeking to meet an elevated, yet indeterminate, professional standard of care. Should companies stop patenting in Canada? Should patent applications be abandoned if an examiner issues a rejection based on prior art? On the contrary, not only can a properly-coordinated global patent prosecution strategy address the risks associated with Canadian prior art objections, but careful compliance with the duty of candour can sanitise a patent application so that it is as potent as possible when litigation ensues.

The key: a coordinated patent strategy

The content of the duty of candour has not yet been fleshed out by Canadian courts, and it is still possible that an appellate court will revisit the issue and limit the scope of the duty of candour. However, as of today, the duty of candour exists, meaning that more care will be required in prosecuting Canadian patents. Here are four tips to assist companies in complying with their newfound prosecution obligations while not compromising their global patent protection objectives:

Do not depart from positions taken in respect of foreign patents

Often, Canadian patent agents are not in a position to determine whether an office action response reflects a full and frank account of the applicant's knowledge relating to a particular prior art issue. This is because the Canadian agent is normally not the agent responsible for doing prior art searches or having knowledge of prosecution abroad.

Canadian courts have been critical of patent prosecution carried out by patent agents who fail, for a lack of knowledge or otherwise, to accurately represent the invention as developed by the inventors. One of Canada's most reputable patent judges, Justice Roger Hughes, recently criticised Pfizer's patent prosecution for its amlodipine besylate patent, which was carried out by an in-house patent agent trainee with little knowledge of the applicable chemistry, and who had little guidance from the inventors (Ratiopharm Inc v Pfizer Limited, Federal Court, 2009). In part based on intentionally misleading misstatements found within the patent, the Court invalidated the patent.

Following Memantine and the Court's scrutiny of slipshod prosecution, litigants can now expect patent defendants to use foreign filings and prior inconsistent statements made to foreign patent authorities in advancing their duty of candour defence. To overcome such attacks, companies should stay consistent with relevant positions taken before foreign patent examiners for any corresponding or related patent. This will permit the Canadian agent to know whether the company is meeting the "full and frank disclosure" standard articulated by the Federal Court in Memantine.

To minimise the risk of inconsistency between Canadian and foreign applications, companies should not only harmonise their international advocacy before the various patent offices, they should also carefully consider making their Canadian claims correspond with claims submitted in other countries. Even though the Canadian Patent Office often allows broader claims than those approved in other jurisdictions, an applicant may face a dilemma if it obtains a broad claim in Canada that has been rejected as obvious in a foreign jurisdiction. An anomalously broad Canadian claim invites the scrutiny of the court, and the reward for aggressive Canadian prosecution may well be a court finding that the entire patent was retroactively abandoned.

Ask the question: If I omit this information, am I ceasing to be "full and frank" in my disclosure?

In a contentious prosecution, it is often unavoidable to take a strong position on a key issue. As knowledgeable practitioners, Canadian patent agents are normally aware of the strengths and weaknesses of their position, and it is expected that strengths will be emphasised, and weaknesses minimised, in office action responses. However, an adversarial approach to advocacy before the Patent Office has suddenly become a much riskier proposition.

Full and frank disclosure requires that companies carefully consider what they have omitted from an office action response in the course of advocating their position. In the Memantine case, Lundbeck was penalised for failing to discuss a prior art reference in response to an obviousness rejection, even though the company had brought the reference to the examiner's attention. After Memantine, prudent applicants will at least acknowledge the existence of information known to be directly relevant to the patentability issue raised by the examiner.

Emphasise facts over argument in advocating before the Patent Office

Canadian office action responses should be reviewed carefully for unnecessary rhetoric. In finding that Lundbeck had violated the duty of candour in Memantine, the Court focused primarily on a single statement made by Lundbeck's Canadian agent in an office action response:

It is therefore the applicant's opinion that the teachings of the prior art as a whole would not have prompted the skilled person, faced with the problem of formulating a composition for the treatment of mild cognitive impairment or dementia, to elaborate the instant composition and that consequently the claims on file are not obvious in view of the prior art. Therefore, withdrawal of this objection is respectfully requested.

By drawing a conclusion regarding "the teachings of the prior art as a whole [emphasis added]", Lundbeck's agent suddenly placed an onerous obligation on itself with respect to the entire body of relevant prior art. Was this necessary to properly respond to the patent examiner? Likely not. Had Lundbeck merely concluded its response simply by stating that the claims were not obvious, the Court may have identified nothing misleading in the response, thereby saving the patent.

Patent law issues are especially complex and ill-suited for application of the principle of res ipsa loquitur (meaning literally, the thing speaks for itself). However, patent applicants would be wise to present prior art information to patent examiners in a more dispassionate style than has traditionally been used, allowing the facts to speak for themselves. Submissions should be heavy on persuasive facts and light on forceful rhetoric, except where such rhetoric is fully supported by the entire factual record.

Seek updated information on your Canadian prosecution obligations at regular intervals

As of today, the law imposes a duty of candour of patent applicants, meaning that more care is required in prosecuting Canadian patents. However, the law relating to Canadian prosecution obligations is in flux, and it is possible that the Federal Court of Appeal will face a similar question and express disagreement with the Memantine decision, leading to a narrowing or non-recognition of the duty of candour. Innovators would be wise to be mindful of Memantine but to also watch for future court decisions that dictate the rules of engagement for innovative companies before the Canadian Patent Office.

The Memantine decision

The Memantine decision resulted from an administrative patent proceeding under Canada's Patented Medicine (Notice of Compliance) Regulations, wherein Lundbeck sought an order prohibiting ratiopharm from obtaining authorisation from Health Canada to market its generic memantine (marketed under the name Ebixa) product. Lundbeck asserted two patents, one of which – Canadian patent number 2,426,492 (the 492 Patent) – involved the use of memantine, an Alzheimer's drug – in combination with one of several cholinesterase inhibitors also indicated in the treatment of Alzheimer's. The Court found that the second patent did not pose a barrier to market entry.

The Court addressed ratiopharm's allegation that the 492 Patent had been abandoned, and this is where it delved into the existence and scope of the duty of candour in Canada. The Court's analysis arises from paragraph 73(1)(a) of the Patent Act, which deems an application for a patent to be abandoned if, amongst other things, the applicant does not "reply in good faith to any requisition made by an examiner in connection with an examination, within six months after the requisition is made or within any shorter period established by the Commissioner" [emphasis added].

Ratiopharm alleged that the applicants for the 492 Patent misrepresented during examination that the prior art "taught away" from using a combination of memantine and a cholinesterase inhibitor in the treatment of Alzheimer's disease. Although ratiopharm and the Court acknowledged that a key prior art document by Wenk had been brought to the attention of the Patent Office, ratiopharm alleged that the applicants failed to discuss the significance or provide a copy of the Wenk article in responding to an office action finding of obviousness.

In its office action response, the applicants discussed several pieces of prior art that, taken together, could have been taken to suggest that a skilled person would not have been motivated to combined memantine with a cholinesterase inhibitor. The response then went on to conclude that:

It is therefore the Applicant's opinion that the teachings of the prior art as a whole would not have prompted the skilled person, faced with the problem of formulating a composition for the treatment of mild cognitive impairment or dementia, to elaborate the instant composition and that consequently the claims on file are not obvious in view of the prior art. Therefore, withdrawal of this objection is respectfully requested [emphasis added].

In reviewing this exchange of communication, Justice Mactavish of the Federal Court first affirmed that s. 73(1)(a) imposes a duty of candour on the part of applicants in the prosecution of a patent application in Canada.

In affirming the existence of this duty, Mactavish drew on Justice Hughes's reasoning in GD Searle & Co v Novopharm Ltd (2007). Mactavish accepted Hughes's analysis as an accurate overview of the obligations on an applicant. In particular, she approved of Hughes's analogy between an application for a patent and an ex parte court proceeding, finding that "the ordinary checks and balances of the adversary system are not operative".

In applying the duty of candour, Mactavish observed that the patent examiner was concerned with obviousness, and in particular the obviousness of combining memantine with cholinesterase inhibitors for the treatment of mild cognitive impairment or dementia. Instead of alerting the examiner to the importance of the Wenk article, the patent agents advised the patent examiner of other articles warning against combining NMDA antagonists (of which memantine is one) with cholinesterase inhibitors because NMDA antagonists attenuate the effect of the cholinesterase inhibitors.

Missing from the patent agents' office action response was the fact that Wenk was directly relevant to the claimed combinations (unlike the articles cited), and that Wenk came to the opposite conclusion of those other articles. Specifically, Wenk explained that certain "reversible" cholinesterase inhibitors such as those contemplated in the 492 Patent did not lose their therapeutic effect when used in conjunction with memantine. In view of Wenk, Mactavish found that the patent agents did not fairly represent the teachings of the prior art when they said that "the prior art clearly teaches away" from the invention alleged in the 492 Patent. Prior disclosure of the existence of the Wenk article did not change the fact that the statements made in the response "were not a full, fair or complete depiction of the teachings of the prior art". There is no appeal possible from this decision.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Bereskin & Parr LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Bereskin & Parr LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions